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Daynene Vykoukal, PhD,a and Mark G. Davies, MD, PhD, MBA,a,b Houston, Tex
The metabolic syndrome is a constellation of clinical risk factors comprising atherogenic dyslipidemia (low high-density
lipoprotein and high triglycerides levels), elevated blood pressure, elevated plasma glucose, a prothrombotic state, and a
proinflammatory state accompanied by an increased risk for cardiovascular disease and type 2 diabetes mellitus. The
adipose tissue of obese humans contains increased numbers of macrophages, and once activated, these macrophages are
responsible for the expression of most of the tissue’s tumor necrosis factor (TNF)- and interleukin (IL)-6. Chronic
inflammation associated with visceral obesity induces altered lipoprotein metabolism and insulin resistance in the liver.
Adipocytes secrete a variety of hormones, cytokines, growth factors, and other bioactive substances, conceptualized as
adipocytokines, including plasminogen activator inhibitor 1 (PAI-1), TNF-, leptin, and adiponectin. The dysregulation
of these adipokines contributes to the pathogenesis of obesity. Adipose tissue-resident macrophages and adipocytes in the
adipose tissue combined with the consequences of hyperglycemia, altered lipoproteins, and hyperinsulinemia in the
vasculature and within organ microcirculation lead to dysfunctional endothelia and a proinflammatory state. Metabolic
syndrome thus represents a combination of synergistic vascular pathologies that lead to an accelerated atherogenic state
that compromises the ability of the patient to satisfactorily respond to humoral, cellular, and mechanical stresses. ( J Vasc
Surg 2011;54:819-31.)
Clinical Relevance: The incidence of metabolic syndrome is rapidly approaching epidemic levels. Cardiovascular
morbidity and mortality increases 1.5-fold to 3-fold in the presence of the metabolic syndrome. Metabolic syndrome is
a constellation of risk factors of metabolic origin characterized by hyperinsulinemia, low glucose tolerance, and truncal
obesity. The syndrome is associated with atherogenic dyslipidemia (low high-density lipoprotein and high triglycerides
levels), elevated blood pressure, elevated plasma glucose, and a prothrombotic and a proinflammatory state that act
synergistically to produce a proinflammatory prothrombotic state in the vascular patient. Identifying the patient with
metabolic syndrome and understanding its biology is key to developing preventive interventions and therapeutic
strategies.
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tThe metabolic syndrome is a constellation of risk fac-
tors of metabolic origin that are accompanied by an in-
creased risk for cardiovascular disease and type 2 diabetes
mellitus. Insulin resistance, which results in this risk-factor
clustering, may contribute to many of the untoward out-
comes attributed to the metabolic syndrome.1 The clinical
risk factors are atherogenic dyslipidemia, defined as low
high-density lipoprotein (HDL) and high triglycerides lev-
els, elevated blood pressure and plasma glucose levels, a
prothrombotic state, and a proinflammatory state (Fig 1).
The metabolic syndrome is also characterized by hyperin-
sulinemia, low glucose tolerance, and truncal obesity. Lipid
profile abnormalities, such as elevated serum triglyceride
and reduced HDL levels, have been found in most studies
of intermittent claudication,2 and there is a strong inverse
relationship between HDL levels and claudication sever-
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doi:10.1016/j.jvs.2011.01.003ty.3 An estimated 50% of diabetic patients have evidence of
eripheral artery disease.4 However, a study of 100 consec-
tive nondiabetic patients attending a vascular clinic
howed abnormal results for glucose tolerance tests in
0%.5 This was despite all 40 patients having random or
asting blood glucose levels that were within normal refer-
nce ranges.
Two definitions of metabolic syndrome predominate in
he literature, the National Cholesterol Education Program
NCEP) and the World Health Organization (WHO; Ta-
le I). Metabolic syndrome is defined as the presence of
hree or more of the following: (1) waist circumference
88 cm in women and 102 cm in men; (2) fasting
riglycerides 150 mg/dL or drug treatment for elevated
riglycerides; (3) HDL-cholesterol50 mg/dL in women
nd 40 mg/dL in men or drug treatment for reduced
DL-cholesterol; (4) blood pressure130/85 mmHg or
se of blood pressure-lowering medication; and (5) fasting
lucose 100 mg/dL or use of glucose-lowering medica-
ion.6 If waist circumference is not available, a body mass
ndex (BMI) 30 kg/m2 can be used as a determinant for
bdominal obesity.7
The prevalence of metabolic syndrome in the adult pop-
lation in developing countries is 22% to 39% and varies
epending on the definition used and on ethnicity.8-10 The
HO or NCEP definitions (Table I) both associate meta-
olic syndrome with future coronary heart disease events and
ype 2 diabetes. Both definitions will predict cardiovascular
ortality, whereas the NCEP definition can predict all-cause
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September 2011820 Vykoukal and Daviesmortality. Although the age-dependent prevalence of meta-
bolic syndrome is between 20% and 40% in healthy individ-
uals,11 metabolic syndrome is present in approximately 45%
of patients with symptomatic peripheral vascular disease
and is higher in those with lower extremity atherosclerotic
occlusive disease (prevalences of 52% to 58%).12,13
OBESITY, ADIPOCYTES, LIPIDS, AND
ADIPOKINES
Obesity and adipose tissue. In humans, two types of
adipose tissue have been defined that are considered to have
essentially antagonistic functions: white adipose tissue
(WAT) stores excess energy as triglycerides, and brown
adipose tissue (BAT) is responsible for the dissipation of
energy through the production of heat. BAT is abundant in
small mammals and in newborns and helps them survive
cold temperatures.14 Recent investigations, however, have
shown that adults also have metabolically active BAT and
that BAT may play an important role in energy homeosta-
sis. WAT stores energy in the form of triglycerides, and
accumulated WAT is the adipose tissue responsible for
metabolic syndrome.
Adipose tissue is a heterogeneous mix of adipocytes,
stromal preadipocytes, immune cells, and endothelium.15
Adipose tissue develops in several distinct anatomic depots,
and the differential expansion of these depots is of great
importance. Expansion of visceral or abdominal WAT has
been most strongly correlated to insulin resistance and
cardiovascular disease in humans and animals.16 Con-
versely, expansion of subcutaneous WAT does not appear
to have the same negative systemic consequences on me-
Fig 1. Metabolic syndrome is characterized by atherogenic dys-
lipidemia (low high-density lipoprotein and high triglycerides lev-
els), elevated blood pressure, elevated plasma glucose, a prothrom-
botic state, and a proinflammatory state. This is a result of an
increase in adipocyte mass (A) and macrophage infiltration (M) in
the fat tissue and in organs. The presence of elevated blood
pressure, elevated blood glucose and serum free fatty acids, hyper-
insulinemia, and insulin resistance leads to dysfunction in skeletal
muscle, liver, and microcirculations. The secretion of myokines,
adipokines, and cytokines acts synergistically to enhance the met-
abolic state and drive end organ dysfunction.tabolism.17 Adipose tissue possesses a relatively dense net- sork of blood capillaries, ensuring adequate exposure to
utrients and oxygen. WAT varies in its vascularity, both
etween depots and within the tissue.18 The balance be-
ween angiogenesis and hypoxia has a significant impact on
he modulation of “good” vs “bad” tissue expansion,
hereby implicating the local microvasculature as a key
odulator of the systemic impact of adipose depots.17,19,20
The adipose tissue of obese humans contains increased
umbers of macrophages, and once activated, these mac-
ophages secrete a range of cytokines such as tumor necro-
is factor (TNF)-, interleukin (IL)-6, and IL-1.21 The
acrophages resident in the adipose tissue are responsible
or the expression of most of the tissue’s TNF- and IL-6.
he expression of macrophage markers in human adipose
issue is high in subjects with obesity and insulin resistance,
nd can be correlated with the expression of TNF- and
L-6.22,23 Adipocytes express low levels of monocyte che-
oattractant protein (MCP)-1, and increased expression is
ound in obese individuals.23
Recent studies suggest that macrophages infiltrate adi-
ose tissue as part of a scavenger function in response to
dipocyte necrosis. Immunohistologic studies of human
dipose tissue have demonstrated that most of the macro-
hages in adipose tissue surround dead adipocytes and form
syncytium, often referred to as a “crown-like structure,”24
nd the macrophage burden surrounding necrotic adi-
ocytes increases significantly.25 The adipocyte secretes
everal factors that modulate the production of new blood
essels, including angiopoietin-1, angiopoietin-2, vascular
ndothelial growth factor (VEGF), transforming growth
actor (TGF)-, hepatic growth factor (HGF), stromal
erived factor 1, TNF-, resistin, leptin, tissue factor, pla-
ental growth factor, and insulin-like growth factor.26
There is evidence suggesting that the vascular network
orms before the mature lipid-carrying adipocytes reside in
he area, thus providing access of secreted cytokines and
dipokines to the circulation.18 Despite this great angio-
enic potential, the rapidly expanding fat pad still experi-
nces hypoxia and necrosis.27,28 The induction of adi-
ocyte hypoxia in vitro results in the expression of a number
f inflammatory cytokines.29-31
The adipose tissue expandability hypothesis states that
failure in the capacity for adipose tissue expansion, rather
han obesity per se, is the key factor linking positive energy
alance and type 2 diabetes. Each individual possesses a
aximum capacity for adipose expansion, which is deter-
ined by genetic and environmental factors. Once the limit
f adipose tissue expansion is reached, adipose tissue ceases
o store energy efficiently and lipids begin to accumulate in
ther tissues. Ectopic lipid accumulation in nonadipocyte
ells induces insulin resistance, apoptosis, and inflamma-
ion.32 Adipocytes are potent sources of such adipokines,
hich mediate many parts of the biology encountered. The
wo types of adipocytokines are (1) adipose tissue-specific
ioactive substances (true adipokines) and (2) adipokines
hat are abundantly secreted from adipose tissue but are not
pecific for adipose tissue.
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Volume 54, Number 3 Vykoukal and Davies 821Lipoprotein metabolism. Obesity, an increased mass
of activated adipocytes and their linked changes in lipopro-
teins, is a major component in the biology of metabolic
syndrome. Chronic inflammation associated with visceral
obesity induces altered lipoprotein metabolism and insulin
resistance in the liver.33 Abnormalities in the transport of
lipoprotein diminish the catabolism of very low-density
lipoprotein (VLDL) and increase the catabolism of HDL,
which creates insulin resistance. This process is associated
with a lower concentration of the adipokine adiponectin
(vide infra) that in turn regulates the catabolism of VLDL
and HDL, consequently increasing the flow of fatty acids
from the adipose tissue to the liver and muscles.34
Accumulation of lipid metabolites within nonadipose
tissues can induce chronic inflammation by promoting
macrophage infiltration and activation and tissue damage.
Oxidized and glycated lipoproteins, free fatty acids (FFAs),
free cholesterol, triacylglycerols, diacylglycerols, and cer-
amides induce cellular dysfunction through their proin-
flammatory and proapoptotic properties.35 Emerging evi-
dence also suggests that macrophage activation by lipid
metabolites and further modulation by lipid signaling rep-
resents a common pathogenic mechanism underlying lipo-
toxicity in atherosclerosis, obesity-associated insulin resis-
tance, liver steatosis, and chronic kidney disease. Lipid
derivatives, through modulation of macrophage function,
promote plaque instability in the arterial wall, impair insulin
responsiveness, and contribute to inflammatory liver, mus-
cle, and kidney disease.35
In metabolic syndrome, the regulation of fat storage
and energy supply by adipose tissue is impaired, leading to
elevated plasma FFA levels, excessive metabolism of FFAs,
and high levels of FFA metabolites in nonadipose tissue.36
FFAs and their metabolites act as metabolic mediators of
insulin resistance. It has been proposed that insulin resis-
tance occurs in adipose tissue before muscle insulin resis-
tance.37 In adipose tissue, insulin resistance of obesity is
characterized by an inadequate insulin action in the fed
Table I. Definitions of metabolic syndrome
Variable NCEP AT
Absolutely required None
Criteria Any 3 of the 5 criteria belo
Obesity Waist circumference: 40
Hyperglycemia Fasting glucose 100 mg/d
Dyslipidemia Triglycerides 150 mg/dL
Dyslipidemia (second, separate
criteria)
HDL-C 40 (M), 50 mg
therapy
Hypertension 130 mm Hg systolic of 
or on therapy
ATP, Adult Treatment Panel III; BMI, body mass index; F, female; HDL
impaired fasting glucose; IR, insulin resistance; M, male; NCEP, Nationa
Organization.state that resembles conditions in the normal fasting state. fhis results in the release of FFAs into the circulation to
eliver energy to skeletal muscle. Thus, postprandial FFAs
re directly transported to the skeletal muscles and the liver,
here energy is not needed. FFAs and their metabolites
lso act as signaling molecules interacting with insulin
ignaling38 and have direct effects on glucose trans-
ort.36,39,40 Reducing ectopic fat in the skeletal muscle of
iabetic patients might therefore be a promising target for
iabetes therapy and might partly explain the action of
hiazolidinedione, a drug used to treat diabetes.41
Adipokines. Adipocytes secrete a variety of hormones,
ytokines, growth factors, and other bioactive substances,
onceptualized as adipocytokines, including plasminogen
ctivator inhibitor 1 (PAI-1), TNF-, leptin, and adiponec-
in (Table II).42 Dysregulated production of these adipocy-
okines is part of the pathogenesis of metabolic syndrome
Fig 2). Increased productions of PAI-1 and TNF- from
ccumulated fat contribute to the formation of thrombosis
nd insulin resistance in obesity, respectively. A lack
f leptin causes metabolic syndrome. Adiponectin exerts
nsulin-sensitizing and antiatherogenic effects; hence, a de-
rease of plasma adiponectin is causative for insulin resis-
ance and atherosclerosis in obesity.43
Leptin. Leptin is a 167-amino acid hormone secreted
argely by adipose tissue that controls food intake and
nergy expenditure.44 Circulating levels of leptin parallel
at cell stores, increasing with overfeeding and decreasing
ith starvation. Although the absence of leptin or a muta-
ion in leptin receptor genes induces massive hyperphagia
nd obesity in humans,45,46 the prevalence of these muta-
ions in obese humans is rare. The effects of leptin are
ediated by receptors, mainly located in the central ner-
ous system and in other tissues, including adipocytes and
ndothelial cells. Leptin receptor belongs to the class I
amily of cytokine receptors, and it engages both the signal
ransducer and activator of transcription-3 (STAT3) path-
ay and the insulin receptor substrate phosphoinositide-3
inase pathway.47 STAT3 has been shown to be essential
WHO
Insulin resistance (IGT, IFG, T2D, or
other evidence of IR)
IR or diabetes, plus 2 of the 5 criteria
below:
), 35 in (F) Waist/hip ratio: 0.90 (M), 0.85 (F);
or BMI 30 kg/m2
n therapy IR already required
n therapy Triglycerides 150 mg/dL, or HDL-C
35 mg/dL (M), 39 mg/dL (F)
(F); or on
m Hg diastolic; 140/90 mm Hg
gh-density lipoprotein cholesterol; IGT, impaired glucose tolerance; IFG,
lesterol Education Program; T2D, type 2 diabetes; WHO, World HealthP III
w:
in (M
L or o
, or o
/dL
85 m
-C, hior mediating food intake, liver glucose production, and
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September 2011822 Vykoukal and Daviesgonadotropin secretion47; however, the control of adipose
tissue metabolism by leptin is STAT3-independent.48 In-
fusion of leptin into the hypothalamus led to the suppres-
sion of lipogenesis in adipose tissue through activation of
the phosphoinositide-3 kinase pathway, the sympathetic
nervous system, and the engagement of the adipose tissue
endocannabinoid system.46 Leptin modulates the T-cell
immune response, stimulates proliferation of T-helper cells,
and increases production of proinflammatory cytokines by
regulating different immune cells.49,50
Adiponectin. Adiponectin is a 30-kDa protein se-
Table II. Signaling molecules of metabolic syndrome
Cytokines Adipokines Coagulation
TNF- Leptin PAI-1
IL-6 Adiponectin Tissue factor
IL-8 Resistin TIMP-1
IL-10 Visfatin
IL-1R Apelin
IL-1RA Vaspin
TGF- Chemerin
IGF-1 Hepcidin
HB-EGF RBP-4
MCP-1 Omentin
ApoE,Apolipoprotein E;HB-EGF, heparin-binding epidermal growth factor
protein; PAI, plasminogen activator inhibitor;RPB, retinol binding protein 4
of metalloproteinase; TNF, tumor necrosis factor.
Fig 2. The development of metabolic syndrome is a journey from
lean and healthy to white adipose tissue (WAT) expansion and
inflammation, which progresses to obesity and its associated com-
plications. The expansion of WAT is associated with an angiogenic
response and an increase in the infiltration of macrophages (M)
into theWAT. The visceral and truncal WAT alter their production
of adipokines and cytokines, which leads to enhanced inflamma-
tion and a loss of insulin sensitivity (development of insulin resis-
tance). The result of the changes in adipokines and cytokines leads
to hypertension, hyperglycemia, dyslipidemia, and a hypercoagu-
lable state. IL, Interleukin-6; MCP, monocyte chemoattractant
protein; PAI, plasminogen activator inhibitor; TNF, tumor necro-
sis factor.creted from adipocytes.51 Circulating adiponectin is found tn several different isoforms: trimer, low-molecular weight
hexamers), and high-molecular weight (HMW; 18-mers)
orms,52,53 each with distinct biologic functions.54 The
MW isoform is linked to the insulin-sensitizing effects of
diponectin, whereas the central effects of adiponectin are
inked to the hexamer and trimer isoforms.55 Adiponectin
s present in cerebrospinal fluid largely in the trimer and
examer forms.56
Adiponectin increases food intake by enhancing hypo-
halamic 5’-adenosine monophosphate-activated protein
inase activity in fasting conditions.57 Circulating levels of
diponectin are decreased in obesity-induced insulin resis-
ance.58,59 The HMW oligomer of adiponectin is inversely
ssociated with the risk for diabetes independent of total
diponectin levels60 and is responsible for the association of
diponectin with traits of metabolic syndrome.61,62
Adiponectin binds two transmembrane receptors (AdipoR1
nd AdipoR2) that are ubiquitously expressed. AdipoR1 is
redominantly expressed in skeletal muscle, with a prefer-
nce for binding to globular adiponectin, whereas AdipoR2
s most abundant in the liver, with a preference for binding
o full-length adiponectin.63 Adiponectin improves insulin
ensitivity by increasing energy expenditure and fatty acids
nd by the expansion of subcutaneous adipose tissue with
ecreased levels of macrophage infiltration,64 similar to the
ctions of PPAR- agonists. Thiazolidinediones are known
o increase circulating levels of adiponectin, mostly the
MW form, by twofold to threefold65-67 and improve
nsulin resistance by diversion of fat from ectopic sites to
ubcutaneous adipose tissue.68 Interestingly, the insulin-
ensitizing effects of thiazolidinediones are significantly
iminished in the absence of adiponectin,69 suggesting an
mportant role of adiponectin in reduction of the lipotox-
city and inflammation associated with obesity. Adiponectin
as also had vasculoprotective effects through an increase in
ndothelial nitric oxide (NO) production and modulation
f the expression of adhesion molecules and scavenger
eceptors.70,71
Resistin. Resistin is a 12-kDa peptide that is part of a
ene family of “resistin-like molecules,” produced by resis-
Hypertension Adipocyte related
Angiotensinogen Acylation stimulating protein
Prostaglandins Monobutyrin
Oxygen free radicals Adipsin
Adiophilin
ApoE
Pentraxin-3
SAA
Agouti
1 acid glycoprotein
insulin-like growth factor; IL, interleukin;MCP,monocyte chemoattractant
, serum amyloid A;TGF, transforming growth factor;TIMP, tissue inhibitor; IGF,in.72 Resistin is expressed by adipocytes in mice but is
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Volume 54, Number 3 Vykoukal and Davies 823expressed by the macrophages of humans.73 Resistin is a
12-kDa protein that circulates as either a trimer (mono-
meric form of the peptide hormone) or hexamer (dimeric
form of resistin). The monomeric form was shown to
impair hepatic insulin action more potently than the
dimerized form.74 In contrast, the dimerized form of resis-
tin was more effective in antagonizing insulin-stimulated
glucose uptake in adult murine cardiomyocytes.74
A number of studies have examined plasma resistin
levels or adipose resistin expression and have found variable
associations with insulin resistance.75-78 High plasma levels
of resistin correlate with proatherogenic inflammatory
markers, metabolic syndrome, increased cardiovascular
risk, unstable angina, and poor prognosis in coronary artery
disease. Resistin increases proinflammatory markers and
induces the release of endothelin 1 and the production of
vascular cell adhesion molecule 1 and MCP-1. A recent
large study involving the Framingham offspring cohort
found a significant relationship between insulin resistance
and resistin; however, this relationship was considerably
weaker than the relationship with adiponectin and was lost
after adjustment for BMI.79 Resistin decreases after thiazo-
lidinediones treatment of humans, although resistin was
also decreased by metformin treatment.65,80
Retinol binding protein 4. Retinol binding protein 4
(RBP4) is a highly expressed circulating adipokine that can
lead to insulin resistance. Many studies have demonstrated
a positive association between RBP4 and insulin resistance
or obesity, whereas others have not. There are suggestions
of an age-related difference, with younger people demon-
strating the relation while older persons do not.81 RBP4 is
associated with adipose tissue macrophage markers, sug-
gesting a link between RBP4 and inflammation within
adipose tissue.82 RBP4 circulates bound to transthyretin,
which decreases RBP4 renal clearance, and transthyretin
plasma levels are increased fourfold in murine models of
metabolic syndrome.83 There is an association of RBP4 and
Glut4, which is presumed to play a role in fuel sensing in the
adipocyte.
Visfatin. Visfatin is expressed in many cells and tissues
and was previously identified as a protein involved in B-cell
maturation (pre-B colony-enhancing factor).84,85 Visfatin
has insulin-like functions and is predominantly found in
visceral adipose tissue.86 Human studies noted a positive
correlation between visceral adipose tissue visfatin gene
expression and BMI, along with a negative correlation
between BMI and subcutaneous fat visfatin,87,88 suggest-
ing that visfatin regulation in these different depots is
different and that adipose depot ratios are highly depen-
dent on the obesity of the individuals. No difference in
visfatin expression between fat depots of humans was
noted,87,88 and visfatin was expressed predominantly by
nonmacrophage cells in the adipose tissue stroma.88 Plasma
visfatin can be positively associated with BMI.87 Visfatin
can upregulate IL-6 and TNF- in vivo and in vitro.74
Visfatin can increase matrix metalloproteinase-9 (MMP-9)
activity in monocytes as well as TNF- and IL-8 in periph-
eral blood mononuclear cells.89 aTissue inhibitor of metalloprotease-1. Tissue inhib-
tor of metalloprotease-1 (TIMP-1), another new candi-
ate adipokine, is the constitutive inhibitor for the gelati-
ase MMP-9. The expression and secretion of TIMP-1 are
pregulated by proinflammatory cytokines in obese pa-
ients and in vitro, so it is possible that TIMP-1 has a role in
aintaining adipose tissue mass in obesity.90,91
Heparin-binding epidermal-growth factor-like growth
actor. Heparin-binding growth factors are a family of mi-
ogenic proteins that have varying affinities for heparin and
eparin-like molecules. They include platelet-derived
rowth factor, acidic fibroblast growth factor (FGF), basic
GF, VEGF, HGF, and heparin-binding epidermal growth
actor (HBEGF). HBEGF is expressed in adipocytes, and
ts plasma levels increase with the extent of obesity.
BEGF is a 22-kDa growth factor that is mitogenic for
broblasts and smooth muscle cells. It acts by binding to
he EGF receptor and, in fact, has a greater affinity for EGF
eceptors on smooth muscle cells and is a more potent
itogen for smooth muscle cells than EGF itself.
Angiotensinogen. The angiotensinogen gene is de-
ected in adipose tissue, although messenger RNA (mRNA)
xpression is not correlated with adiposity. Angiotensino-
en is the precursor of angiotensin I, which after conversion
o angiotensin II, plays a major role in blood pressure
egulation. Angiotensinogen mRNA expression is in-
reased in visceral fat,92,93 which partially explains the
elationship between systemic hypertension and obesity in
he metabolic syndrome. Angiotensinogen knockout mice
ith selective overexpression of angiotensinogen in adipose
issue develop obesity with a high-fat diet and especially
ypertension, which is compatible with involvement of
dipose tissue angiotensinogen secretion in the genesis of
his phenotype.94
Omentin. Omentin is a secretory protein that has
een recently identified as a new adipokine encoded by two
enes (1 and 2) that is highly and selectively expressed in
isceral adipose tissue. Omentin may regulate insulin ac-
ion. Omentin 1 plasma levels and adipose tissue gene
xpression are decreased with obesity, and they correlate
ositively with plasma adiponectin and HDL and nega-
ively with waist circumference, BMI, and insulin resis-
ance.95 Omentin transcripts are strongly expressed in vis-
eral adipose tissue but poorly in subcutaneous fat.
mentin is present in the stromal vascular cells of omental
dipose tissue but not in mature fat cells. Human omentin
s a peptide of 313 amino acids and contains a secretory
ignal sequence and a fibrinogen-related domain.96 It is
ecreted in the culture medium of omental but not subcu-
aneous fat explants. Interestingly, it increases insulin-
timulated glucose uptake in both omental and subcutane-
us adipocytes and promotes Akt phosphorylation.97
Chemerin. Chemerin is a novel and promising adipo-
ine whose plasma levels in humans have been found to be
ignificantly associated with BMI, circulating triglycerides,
nd blood pressure.98 Chemerin or chemerin receptor
nockdown impairs differentiation of 3T3-L1 cells into
dipocytes, reduces the expression of adipocyte genes in-
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September 2011824 Vykoukal and Daviesvolved in glucose and lipid homeostasis, including adi-
ponectin and leptin, and alters metabolic functions in ma-
ture adipocytes.99
Apelin. Apelin is an adipokine produced and secreted
by adipocytes, whose plasma levels are significantly elevated
by obesity and insulin in humans, which was found to be
the endogenous ligand for the G protein-coupled APJ
receptor. The gene that encodes the apelin receptor shares
the greatest sequence identity with the angiotensin AT1
receptor.100 Apelin production is upregulated by hypoxia.
Apelin has been shown to exert potent positive inotropic
effects on both normal and failing myocardium. The car-
diac apelin system is downregulated by angiotensin II, and
its restoration is reached by treatment with angiotensin
type 1 receptor blocker.
Vaspin. Vaspin is an adipokine recently identified as a
member of the serine protease-inhibitor family.101 It is
strongly expressed in visceral adipose tissue and is stimu-
lated in mouse and human obesity.102 Its tissue expression
and plasma levels are normalized in the presence of insulin
or an insulin-sensitizing drug (pioglitazone).103
Serum amyloid A. Serum amyloid A (SAA), an in-
flammatory acute-phase protein associated with systemic
inflammation and atherosclerosis, is used as a predictive
marker in coronary accidents or cardiovascular events. Cir-
culating levels of SAA are significantly correlated with
insulin resistance in obesity and type 2 diabetes.104 SAA is
expressed in adipose tissue, and this expression is largely
increased in obesity and diabetes.105,106 Also, SAA could
participate in lipoprotein metabolic alterations, promoting
the linking of HDL-cholesterol to macrophages, thus re-
ducing their cardiovascular-protective effect.
C-reactive protein. C-reactive protein (CRP) mRNA
is detected in adipocytes. Adiponectin knockout mice show
higher plasma CRP levels than wild-type mice. The strong
negative correlation between adiponectin mRNA and CRP
mRNA expression in human adipose tissue suggests that a
decrease in adiponectin leads to a rise in CRP. CRP can
inhibit insulin-evoked NO production in endothelial cells
through specific inactivation of the PI3K/Akt/endothelial
NO synthase pathway.107,108 Similar to TNF-, CRP si-
multaneously increases endothelin (ET-1) production.108
Thrombospondin-1 and CD36. One of the newer
adipokines is thrombospondin-1 (TSP-1), a multidomain,
multifunctional glycoprotein synthesized by many cell
types, which modulates cell adhesion and proliferation.
TSP-1 is a major activator of TGF-1 in vivo.109 As a result,
TSP-1 is involved in angiogenesis, inflammation, and
wound healing. CD36 is the receptor for TSP-1 and is
present on platelets, mononuclear phagocytes, adipocytes,
hepatocytes, myocytes, and some epithelia.110 On phago-
cytes, it functions as a scavenger receptor, recognizing
specific oxidized phospholipids and lipoproteins. CD36
also binds long-chain fatty acids and facilitates their trans-
port into cells, thus participating in muscle lipid utilization,
adipose energy storage, and gut fat absorption, and possibly
contributing to the pathogenesis of metabolic disorders,
such as diabetes and obesity. The chemotactic properties of tSP-1111 provide a link between TSP-1 and macrophage-
ediated adipocyte inflammation. In addition, adipocyte-
acrophage coculture experiments demonstrated TSP-1
ene and protein upregulation by both cell types, suggest-
ng a feed-forward inflammatory mechanism in adipose
issue.112 TSP-1 may be an important component of in-
ammation and coagulation in themetabolic complications
f obesity.
NSULIN RESISTANCE AND HYPERGLYCEMIA
Insulin resistance. Insulin resistance is the second key
iologic component of the metabolic syndrome. Chronic
nflammation associated with visceral obesity induces insu-
in resistance in the liver.33 This chronic inflammation is
haracterized by the production of abnormal adipokines
nd cytokines such as TNF-, FFA, IL-1, IL-6, leptin, and
esistin. These factors inhibit insulin signaling, which in
urn causes impaired suppression of glucose production by
nsulin in hepatocytes and leads to hyperglycemia.
An important and early complication of hepatic insulin
esistance is the induction of hepatic VLDL production
hrough changes in the rate of apolipoprotein B synthesis
nd degradation and de novo lipogenesis or increased FFA
ux from adipose tissue into the liver. Insulin resistance also
timulates the production of CRP and PAI-1, both markers
f an inflammatory state. All metabolic abnormalities re-
ated to hepatic insulin resistance have been shown to
irectly or indirectly promote atherosclerosis.
Insulin has several direct vascular actions that contrib-
te to vascular protection or injury, depending on the cell
ype. Vascular-protective effects of insulin include stimula-
ion of endothelial cell production of the vasodilator NO.
his, in turn, inhibits formation of lesions dependent on
igration and proliferation of vascular smoothmuscle cells,
ttenuates binding of inflammatory cells to the vascular
all, and inhibits thrombosis by reducing platelet adhesion
nd aggregation. However, insulin also promotes a host of
eleterious vascular effects by stimulating the actions of
arious growth factors, including angiotensin II and PAI-1.
Glucocorticoid metabolism is also abnormal in insulin-
esistant states. Adipocyte-derived hormones, including
diponectin and leptin, regulate systemic insulin sensitivity
n accordance to existing triglyceride reserves. Leptin levels
eflect existing fat mass, and the adipokine negatively reg-
lates insulin action in adipose tissue.
Adiponectin, on the other hand, preserves insulin sensitivity
ia transient increments of 5=-adenosine monophosphate-
ctivated protein kinase activity and its circulating levels
eem to reflect the adipogenic capacity of adipose tissue.
ecause adiponectin and insulin are synergistic, inadequate
diponectin production contributes to systemic insulin
esistance. In insulin-resistant states associated with im-
aired PI3K-dependent insulin signaling pathways, insulin-
ediated ET-1 secretion is augmented, and blockade of
T-1 receptors significantly improves insulin sensitivity and
eripheral glucose uptake in the context of insulin resis-
ance.113,114
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Volume 54, Number 3 Vykoukal and Davies 825Elevated blood glucose levels induce a series of altera-
tions within the vasculature, including endothelial dysfunc-
tion, cellular proliferation, changes in extracellular matrix
conformation, and impairment of LDL receptor-mediated
uptake decreasing the in vivo clearance of LDL concentra-
tions.115-119 The presence of high glucose concentrations
also increases lipoprotein oxidation.120 Elevated glucose
leads to the activation of the sorbitol pathway, cellular
oxidative stress, and formation of advanced glycation end
products (AGE).
AGEcanbeprocessedbymacrophages through a recently
characterized series of high-affinity receptors: scavenger recep-
tors types I and II, the receptor for advanced glycation end
products (RAGE), oligosaccharyltransferase-48 (OST-48,
AGE-R1), 80K-H phosphoprotein (AGE-R2), and galectin-3
(AGE-R3). Coupling of AGE proteins to their AGE recep-
tor results in TNF- and IL-1 synthesis and secretion.
Evidence provided by both clinical and preclinical studies
regarding a central involvement of the RAGE in vascular
disease continues to mount.
RAGE is upregulated as a consequence of diverse in-
flammatory stimuli, including hyperglycemia, oxidized
LDL, and reduced shear stress. RAGE may maintain and
amplify inflammatory responses in the vasculature if the
ligand for the receptor is present. RAGE binding by circu-
lating AGEs or S100 protein released by activated leuko-
cytes results in the generation of reactive oxygen species
and further activation of nuclear factor B. This leads to
upregulation of adhesion molecules for circulating mono-
cytes as well as further upregulation of RAGE itself. In
addition, these reactive oxygen species may scavenge and
reduce bioavailability of the labile vasodilator NO, reduc-
ing its anti-inflammatory effects and possibly compromis-
ing control of vascular tone directly.
ENDOTHELIAL DYSFUNCTION AND
INFLAMMATION
Adipose tissue-resident macrophages and adipocytes in
the adipose tissue and the consequences of hyperglycemia,
altered lipoproteins, and hyperinsulinema in the vascula-
ture and within organ microcirculations induce dysfunc-
tional endothelia and a proinflammatory state in metabolic
syndrome.121
Endothelial dysfunction. Endothelial dysfunction is
an important component of the metabolic syndrome. De-
ficiency of endothelial-derived NO is believed to be the
primary defect that links insulin resistance and endothelial
dysfunction. NO deficiency results from decreased synthe-
sis and/or release, in combination with exaggerated con-
sumption in tissues by high levels of reactive oxygen and
nitrogen species due to cellular disturbances in glucose and
lipid metabolism. Insulin may stimulate endothelial NO
production or may act directly on vascular smooth muscle
by stimulation of the Na–H exchanger and Na/K-
ATPase, leading to hyperpolarization of the cell membrane
and consequent closure of voltage-gated Ca2 channels.
Endothelial dysfunction contributes to impaired insu-
lin action by altering the transcapillary passage of insulin to iarget tissues. Reduced expansion of the capillary network,
ith attenuation of microcirculatory blood flow to meta-
olically active tissues, contributes to the impairment of
nsulin-stimulated glucose and lipid metabolism. Insulin-
nduced vasodilation, which is mediated by the release of
O, is impaired in obese individuals who display insulin
esistance, possibly due to suboptimal levels of (6R)-
,6,7,8-tetrahydrobiopterin (BH4), the natural and essen-
ial cofactor of NO synthases (NOS), and accelerated inac-
ivation of NO by O2– within the vascular wall was
bserved.
A “third factor” may cause both insulin resistance and
ndothelial dysfunction in cardiovascular disease. Candi-
ates include fiber type and capillary density of skeletal
uscle, distribution of adiposity, and endogenous cortico-
teroid production. A complex interaction between endo-
helial dysfunction, abnormal skeletal muscle blood flow,
nd reduced insulin-mediated glucose uptake may be cen-
ral to the link between insulin resistance, blood pressure,
mpaired glucose tolerance, and the risk of cardiovascular
isease.
Tumor necrosis factor-. Of the proinflammatory
ytokines, TNF- is the best described in disturbed insulin
ignaling. Mice lacking TNF- or TNF- receptors are
esistant to the development of obesity-induced insulin
esistance.122,123 In adipose tissue, TNF- is mostly se-
reted by macrophages in the stromal vascular fraction.
irculating TNF- and adipose tissue TNF- gene expres-
ion are increased in insulin resistance,124 and acute infu-
ion of TNF- inhibited insulin-induced glucose uptake in
ealthy individuals.125 Neutralization of TNF- in rodents
as improved insulin resistance,126 whereas attempts to
eutralize TNF- in humans to improve insulin resistance
ave generally not been successful,127 although more re-
ent studies have shown slight improvement in insulin
esistance with TNF- inhibition.128-130 Limited effects of
NF- blockade on insulin resistance could be explained
y the paracrine actions of TNF-. Further investigations
n the mechanisms involved in TNF- overexpression as-
ociated with obesity and molecular signals underlying
NF--induced metabolic dysregulation are warranted.
NF- increases ET-1 secretion and inhibits insulin’s stim-
lating effect on endothelium-dependent vasodilation in
umans.131,132
Interleukin-6. IL-6 is also overexpressed in adipose
issue of the obese.124 The role of IL-6 in metabolic
hanges associated with obesity is unclear. Some reports
how that IL-6 causes impaired insulin signaling in the liver
nd adipocytes by inducing ubiquitin-mediated degrada-
ion of insulin receptor substrate through suppression of
ytokine signaling 1 and 3.133,134 However, effects of IL-6
n insulin sensitivity in skeletal muscle are controversial.134
xercise that is associated with increased insulin action in
keletal muscle increases circulating IL-6 levels dramati-
ally,135 suggesting possible anti-inflammatory roles for
L-6 in skeletal muscle. The data on the increased onset of
besity and diabetes in mice lacking IL-6 are conflict-
ng.136,137 IL-6 also inhibits insulin-stimulated increases in
o
c
t
t
c
s
C
c
s
t
a
f
r
i
n
a
c
p
c
t
r
I
i
c
o
h
g
d
i
m
i
t
t
I
s
g
a
a
e
p
f
fi
n
d
p
a
i
p
f
P
c
P
T
JOURNAL OF VASCULAR SURGERY
September 2011826 Vykoukal and Daviesendothelial NO synthase activity andNO production in the
endothelium.138 IL-1 together with IL-6 concentrations
reportedly predict the risk for type 2 diabetes in humans
better than either cytokine alone.139
Interleukin-10. Decreased production of IL-10, an
anti-inflammatory cytokine, has been associated with the
development of type 2 diabetes, and IL-10 plasma levels
can be positively correlated with insulin sensitivity.140,141
Lower IL-10 levels have been associated with the metabolic
syndrome in obese, insulin-resistant postmenopausal
women compared with women who are obese but do not
satisfy the criteria for metabolic syndrome.142 IL-10 de-
creases IL-6–induced insulin resistance in muscle and liver
in mice cotreated with IL-6 and IL-10.143 A recent study
showed that IL-10 is expressed in macrophages derived
from adipose tissue and that the IL-10 receptor is expressed
in adipocytes and not immune or endothelial cells in fat.144
Several studies indicate that IL-10 is an anti-inflammatory
factor produced by immune cells in adipose tissue that acts
on adipocytes to improve insulin signaling, potentially de-
creasing further macrophage recruitment.
Monocyte chemoattractant protein. Adipocytes se-
crete various chemoattractants that draw monocytes from
the circulation into adipose tissue. MCP-1, also known as
chemokine (C–C motif) ligand 2 (CCL-2), is one the
chemoattractants that is important in the recruitment of
macrophages to the adipose tissues. Moreover, obesity is
associated with increased plasma levels of MCP-1 and over-
expression in adipose tissue.23,145 Mice lacking MCP-1
receptor (CCR-2) have decreased adipose tissue macro-
phage infiltration and improved metabolic function.146,147
Other candidates might likely contribute to the recruit-
ment of macrophages into the adipose tissue, such as
macrophage inflammatory protein-1148 and osteopon-
tin.149,150 Osteopontin is an extracellular matrix protein
that promotes monocyte chemotaxis, and the lack of osteo-
pontin in mice caused improved insulin sensitivity and
decreased macrophage infiltration into adipose tissue.150
HYPERTENSION
Essential hypertension is a complex, multifactorial,
quantitative trait under polygenic control. Increased pe-
ripheral resistance due primarily to changes in vascular
structure and function appear to be the fundamental hemo-
dynamic abnormality in hypertension. These changes in-
clude arterial wall thickening and abnormal vascular tone
and are due to alterations in the biology of the cellular and
noncellular components of the arterial wall. Multiple inter-
acting humoral and mechanical factors as well as oxid-
ative stress stimulate complex signaling pathways, which
modulate vascular smooth muscle cell contraction and
growth.151 Hypertension is one of the commonest compo-
nents of metabolic syndrome and is linked to both essential
hypertension and obesity-related hypertension.152
Excess weight gain is likely the major cause of essential
hypertension, and abnormal kidney function appears to be
a cause as well as a consequence of obesity hypertension.
Excess renal sodium reabsorption and a hypertensive shift ef pressure natriuresis play a major role in mediating in-
reased blood pressure associated with weight gain. Activa-
ion of the renin-angiotensin and sympathetic nervous sys-
ems and physical compression of the kidneys appear to
ontribute to obesity-induced increases in sodium reab-
orption and hypertension.
OAGULATION
Fibrinolytic dysfunction mediates the increased risk of
oronary artery disease in individuals with the metabolic
yndrome.153 Adipose tissue induces thrombocyte activa-
ion by the production of adipokines, some of which, such
s leptin and adiponectin, directly interfere with platelet
unction. Increased adipose tissue mass induces insulin
esistance and systemic low-grade inflammation, also affect-
ng platelet function. Adipose tissue directly impairs fibri-
olysis by the production of PAI-1 and possibly thrombin-
ctivatable fibrinolysis inhibitor.154 Adipose tissue may
ontribute to enhanced coagulation by direct tissue factor
roduction, but hypercoagulability is likely to be primarily
aused by altered hepatic synthesis of the coagulation fac-
ors fibrinogen, factor VII, factor VIII, and tissue factor, by
eleasing FFAs and proinflammatory cytokines (TNF-,
L-1, and IL-6) into the portal circulation and by induc-
ng hepatic insulin resistance. Adipose tissue dysfunction
ould thus play a causal role in the prothrombotic state
bserved in obesity by directly and indirectly affecting
emostasis, coagulation, and fibrinolysis.155
In type 2 diabetes, there are increased levels of fibrino-
en and PAI-1, favoring both thrombosis and defective
issolution of clots once formed. Platelets in type 2 diabetic
ndividuals adhere to vascular endothelium and aggregate
ore readily than those in healthy people. Loss of sensitiv-
ty to the normal homeostatic restraints exercised by pros-
acyclin (PGI2) and NO generated by the vascular endo-
helium present as the major defect in platelet function.
nsulin is a natural antagonist of platelet hyperactivity. It
ensitizes the platelet to PGI2 and enhances endothelial
eneration of PGI2 and NO. Thus, the defects in insulin
ction in diabetes create a milieu of disordered platelet
ctivity conducive to macrovascular and microvascular
vents.156 Patients with type 2 diabetes and abdominal fat
atterning displayed higher plasma activities of clotting
actors VII and VIII as well as increased plasma levels of
brinogen and von Willebrand factor antigen compared
ot only with healthy normal weight controls but also with
iabetic patients at normal body weight.157,158
PAI-1 is elevated in individuals with the metabolic com-
lications of obesity and is expressed in the stromal fraction of
dipose tissue, including endothelial cells.159-163 PAI-1 inhib-
ts both tissue-type plasminogen activator and urokinase-type
lasminogen activator through its serine protease inhibitor
unction and thus contributes to a prothrombotic state.164
AI-1 gene expression is controlled by TGF-, which
ombines with phosphorylated Smad and binds to the
AI-1 promoter.165 A second pathway is by way of TSP-1.
SP-1 is expressed in adipocytes112 and inhibits angiogen-
sis, cell proliferation, and wound healing.111,166 TSP-1 is
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TSP-1 has been described.167 A recent study demonstrated
TSP-1 expression largely by adipocytes compared with the
stromal vascular fraction of adipose tissue, suggesting that
TSP-1 is a true adipokine.112 TSP-1 expression was in-
creased in obese, insulin-resistant individuals, was associ-
ated with plasma PAI-1 levels, and was positively associated
with adipose tissue macrophage markers. In addition,
TSP-1 expression was decreased by treatment of subjects or
adipocytes with the PPAR- agonist, pioglitazone.
Modeling metabolic syndrome. The ideal model for
metabolic syndrome should be obese, hypertensive, insulin
resistant, and have the appropriate dyslipidemia. There is at
present no perfect animal model of this human disease. The
most common models to study metabolic syndrome are
mice that can be based on one of three strategies: obese
mouse strains that mimic metabolic syndrome, mice fed
high-fat diets to induce metabolic syndrome, or gene
knockout mice that mimic metabolic syndrome. Insulin
resistance in mice with differential susceptibility to diabetes
and metabolic syndrome is preceded by differences in the
inflammatory response of adipose tissue. This phenomenon
may serve as an early indicator of disease and contribute to
disease susceptibility and progression.168
The Lepob/ob, LepRdb/db, and Ay/a mice are the three
most commonly used spontaneously mutant obese mouse
models. They display insulin resistance and may develop
diabetes, depending on the background strain. In addition,
Ay/a mice have intact leptin signaling and display a delayed
onset obesity that can be amplified by being fed a high-fat
diet, making them a good model for human obesity. All
three models fall short of an ideal model for metabolic
syndrome.169 Obese mouse models such as Ay/a, Lepob/ob,
and LepRdb/db have increased total plasma cholesterol lev-
els; however, this is the result of increased HDL rather than
increased VLDL and LDL levels. The increase in HDL
makes these mice resistant to atherosclerotic lesion forma-
tion. These lipid changes do not mirror those seen in
metabolic syndrome. Hypertensive mice do not make good
models unless they are crossbred with obese mice.169 Care
should thus be taken to choose the mouse model most
appropriate for the scientific or mechanistic mechanism to
be tested under metabolic syndrome conditions.
CONCLUSIONS
Metabolic syndrome represents a combination of syn-
ergistic vascular pathologies that lead to an accelerated
atherogenic state that compromises the ability of the pa-
tient to satisfactorily respond to humoral, cellular, and
mechanical stresses. Delineating the contribution of insulin
resistance and the role of the adipokines remains a focus of
current research. Defining key signaling pathways may pro-
vide opportunities for new therapeutic targets and interven-
tions. It represents a complex pathology that will require
better definition before the development of satisfactory
therapeutic interventions.UTHOR CONTRIBUTIONS
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